Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma

Background Pancreatic cancer is both common and highly lethal and therefore new biomarkers or potential targets for treatment are needed. Loss of BRCA associated protein-1 (BAP1) expression has been found in up to a quarter of intrahepatic cholangiocarcinomas. Given the close anatomical relationship between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma, we therefore sought to investigate the frequency of loss of BAP1 expression in pancreatic ductal adenocarcinoma. Methods The records of the department of Anatomical Pathology Royal North Shore Hospital, Sydney, Australia, were searched for cases of pancreatic ductal adenocarcinoma diagnosed between 1992 and 2014 with material available in archived formalin fixed paraffin embedded tissue blocks. Immunohistochemistry for BAP1 was performed on tissue microarray sections and if staining was equivocal or negative it was confirmed on whole sections. Negative staining for BAP1 was defined as loss of expression in all neoplastic nuclei, with preserved expression in non-neoplastic cells which acted as an internal positive control. Results Loss of BAP1 expression was found in only 1 of 306 (0.33%) pancreatic ductal adenocarcinomas. This case was confirmed to demonstrate diffuse loss of expression throughout all neoplastic cells in multiple blocks, consistent with BAP1 loss being an early clonal event. All other cases demonstrated positive expression of BAP1. Conclusion We conclude that, in contrast to intrahepatic cholangiocarcinoma, loss of expression of BAP1 occurs very rarely in pancreatic ductal adenocarcinoma. Therefore BAP1 inactivation is unlikely to be a frequent driver abnormality in pancreatic adenocarcinoma.

[1]  Swe Swe Myint,et al.  Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.

[2]  A. Krasinskas,et al.  The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma , 2016, Modern Pathology.

[3]  Ioanna Kougioumtzi,et al.  Malignant pleural mesothelioma: current and future perspectives. , 2013, Journal of thoracic disease.

[4]  R. Murali,et al.  BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma , 2013, Pathology.

[5]  J. Cheville,et al.  Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. , 2016, The Journal of urology.

[6]  C. Amos,et al.  Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. , 2015, Experimental and molecular pathology.

[7]  S. Taylor-Robinson,et al.  Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[8]  T. Pawlik,et al.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.

[9]  H. Popper,et al.  BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma , 2013, Pathology & Oncology Research.

[10]  M. Abdel-Rahman,et al.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers , 2011, Journal of Medical Genetics.

[11]  B. Haugk.  Pancreatic intraepithelial neoplasia – can we detect early pancreatic cancer? , 2010, Histopathology.

[12]  Thomas Wiesner,et al.  Tumours associated with BAP1 mutations , 2013, Pathology.

[13]  S. Grimmond,et al.  Pancreatic cancer genomics: where can the science take us? , 2015, Clinical genetics.

[14]  A. Torrice,et al.  Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. , 2010, World journal of gastrointestinal oncology.

[15]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[16]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[17]  G. Gyapay,et al.  Germline BAP1 mutations predispose to renal cell carcinomas. , 2013, American journal of human genetics.

[18]  G. Rossi,et al.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations , 2015, Modern Pathology.

[19]  W. Weichert,et al.  Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma , 2016, Medicine.

[20]  A. Battaglia.  The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment , 2014, Clinical Medicine Insights. Oncology.

[21]  J. Cheville,et al.  Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. , 2015, Urologic oncology.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  M. Mihm,et al.  BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. , 2015, Human pathology.

[24]  Nuria Lopez-Bigas,et al.  The mutational landscape of chromatin regulatory factors across 4,623 tumor samples , 2013, Genome Biology.

[25]  A. Scarpa,et al.  Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma. , 2012, Surgical oncology.

[26]  A. Biankin,et al.  Pancreatic cancer genomics. , 2014, Current opinion in genetics & development.

[27]  N. Naus,et al.  Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma , 2014, Modern Pathology.

[28]  N. Adsay,et al.  Molecular genetics of pancreatic neoplasms and their morphologic correlates: an update on recent advances and potential diagnostic applications. , 2014, American journal of clinical pathology.

[29]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[30]  C. Toon,et al.  Loss of expression of BAP1 predicts longer survival in mesothelioma , 2015, Pathology.

[31]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[32]  A. Gown,et al.  Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens , 2016, The American journal of surgical pathology.

[33]  A. Husain,et al.  BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. , 2015, Human pathology.

[34]  C. Toon,et al.  Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology , 2015, Modern Pathology.

[35]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[36]  Thomas Krausz,et al.  BAP1 and cancer , 2013, Nature Reviews Cancer.

[37]  C. Toon,et al.  Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. , 2016, Human pathology.

[38]  M. Emi,et al.  Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma , 2012, Cancer science.

[39]  K. Nackaerts,et al.  Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. , 2015, Lung cancer.

[40]  L. Jiao,et al.  Is there a 'margin' for error in pancreatic cancer surgery? , 2013, Future oncology.

[41]  B. Bressac-de Paillerets,et al.  Germline BAP1 mutations predispose also to multiple basal cell carcinomas , 2015, Clinical genetics.

[42]  M. Hoang,et al.  Loss of BAP1 Expression in Basal Cell Carcinomas in Patients With Germline BAP1 Mutations. , 2015, American journal of clinical pathology.